Brand name: Tagrisso
Medication class: Tyrosine kinase inhibitor
Similar drugs: Tarceva (erlotinib), Iressa (gefitinib), Tykerb (lapatinib)
Manufacturer: AstraZeneca Pharmaceuticals
FDA Approval date: November 2015
What is Tagrisso and how does it work?
Tagrisso (osimertinib) is an oral medication used to treat lung cancer. It works by inhibiting tyrosine kinase, which is an enzyme that affects the activity of epidermal growth factor receptors (EGFR). EGFRs are proteins found on the surface of cells, including cancer cells, and allow for the cells to grow. Mutations of EGFR, such as T790M prevent lung cancer drugs from working.
Tagrisso reduces the growth of lung tumor cells that have T790M mutation by binding irreversibly to mutant EGFR receptors and blocking the action of tyrosine kinase, leading to a reduction in the function of EGFR and ultimately a reduction in the growth of the cancer cells. Tagrisso is the first drug approved for EGFR T790M mutation-positive non-small cell lung cancer that progressed despite treatment with other medications.
Tagrisso also blocks the activity of the activity of HER2, HER3, HER4, ACK1, and BLK genes which also play a role in the growth of cancer cells.
What is Tagrisso used to treat?
Tagrisso is used to treat individuals with metastatic epidermal growth factor T790M mutation non-small cell lung cancer (NSCLC) that has progressed on or after previous epidermal growth factor tyrosine kinase inhibitor therapy.
An approved FDA test should be used to confirm the presence of T790M mutation prior to starting treatment with Tagrisso.
Next: Effectiveness (Tumor shrinkage and progression-free survival), Side effects